17. A pharmaceutical composition that comprises a nucleic acid construct according to any of claims 1–9, an expression vector according to any of claims 10-11, a host cell according to claim 12 or a viral particle according to any of claims 13-16, and a pharmaceutically acceptable carrier.

18. A kit comprising a nucleic acid construct according to any of claims 1–9, an expression vector according to any of claims 10-11, a host cell according to claim 12 or a viral particle according to any of claims 13-16 or a pharmaceutical composition according to claim 17 in one or more containers, optionally further comprising instructions or packaging materials that describe how to administer the nucleic acid construct, vector, host cell, viral particle or pharmaceutical composition to a patient.

19. A nucleic acid construct according to any of claims 1–9, an expression vector according to any of claims 10-11, a host cell according to claim 12 or a viral particle according to any of claims 13-16, for use as a medicament.

20. A nucleic acid construct according to any of claims 1–9, an expression vector according to any of claims 10-11, a host cell according to claim 12 or a viral particle according to any of claims 13-16 or a pharmaceutical composition according to claim 17, for use in the treatment of a condition caused by a deficiency or dysfunction of Copper-transporting ATPase 2, preferably in the treatment of Wilson's disease.

21. Use of a nucleic acid construct according to any of claims 1–9, an expression vector according to any of claims 10-11, a host cell according to claim 12, a viral particle according to any of claims 13-16 or a pharmaceutical composition according to claim 17 in the preparation of a medicament for the treatment of a condition caused by a deficiency or dysfunction of Copper-transporting ATPase 2, preferably in the treatment of Wilson's disease.

22. A process of producing viral particles according to any of claims 13-16, comprising the steps of:

a) culturing a host cell according to claim 12 in a culture medium; and

b) harvesting the viral particles from the cell culture supernatant and/or inside the cells.

23. Use of the nucleic acid construct of any of claims 1-9 or the expression vector of any of claims 10-11 for the production of viral particles.